Once B-stage discovery-platform-driven companies start to show impressive clinical results, I think that'll validate the business model. But to actually give the platform a chance to succeed, founders need to keep enough control, or get enough buy-in from leadership/investors,
-
-
Show this thread
-
to actually commit to the platform-driven model all the way into the clinic, instead of pivoting away too early. And that will require some initiative and strategy.
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.